高级检索
当前位置: 首页 > 详情页

3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越:领军期刊 ◇ 中华系列

单位: [1]Department of Immunology, Capital Medical University, Beijing 100069, China [2]Department of Physiology and Pathophysiology, Capital Medical University, Beijing 100069, China [3]Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Capital Medical University, Beijing 100069, China [4]Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China
出处:
ISSN:

关键词: Pulmonary arterial hypertension Monocrotaline 3-Bromopyruvate Aerobic glycolysis

摘要:
Background: Pulmonary arterial hypertension (PH) is a progressive disease with limited therapeutic options, ultimately leading to right heart failure and death. Recent findings indicate the role of the Warburg effect (aerobic glycolysis) in the development of PH. However, the effect of the glycolysis inhibitor 3-bromopyruvate (3-BrPA) on the pathogenesis of PH has not been well investigated. This study aimed to determine whether 3-BrPA inhibits PH and its possible mechanism. Methods: PH was induced in adult Sprague-Dawley rats by a single intraperitoneal injection of monocrotaline (MCT). 3-BrPA, or phosphate-buffered saline (PBS) was administered via intraperitoneal injection every other day from the first day of MCT-injection to 4 weeks of follow-up, and indices such as right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RVHI), pulmonary arteriolar remodeling indicated by percent media thickness (% MT), lactate levels and glucose consumption, were evaluated. Pulmonary arteriolar remodeling and right ventricular hypertrophy were observed in hematoxylin-eosin-stained lung sections. Western blotting, immunohistochemistry, and/or immunofluorescence analyses were used to measure the expression of relevant proteins. A cytochrome C release apoptosis assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling staining were used to measure cell apoptosis. Results: MCT-induced PH showed a significant increase in glucose consumption (0 vs. 4 weeks: 0.87 +/- 0.23 vs. 2.94 +/- 0.47, P = 0.0042) and lactate production (0 vs. 4 weeks: 4.19 +/- 0.34 vs. 8.06 +/- 0.67, P = 0.0004). Treatment with 3-BrPA resulted in a concomitant reduction in glucose consumption (1.10 +/- 0.35 vs. 3.25 +/- 0.47, P = 0.0063), lactate production (5.09 +/- 0.55 vs. 8.06 +/- 0.67, P = 0.0065), MCT-induced increase in RVSP (39.70 +/- 2.94 vs. 58.85 +/- 2.32, P = 0.0004), pulmonary vascular remodeling (% MT, 43.45% +/- 1.41% vs. 63.66% +/- 1.78%, P < 0.0001), and right ventricular hypertrophy (RVHI, 38.57% +/- 2.69% vs. 62.61% +/- 1.57%, P < 0.0001) when compared with those of the PBS-treated group. 3-BrPA, a hexokinase 2 inhibitor, exerted its beneficial effect on PH by decreasing aerobic glycolysis and was also associated with inhibiting the expression of glucose transporter protein-1, inducing apoptosis, and suppressing inflammation. Conclusions: 3-BrPA might have a potential beneficial effect on the PH treatment.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
JCR分区:
出版当年[2018]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Department of Immunology, Capital Medical University, Beijing 100069, China
共同第一作者:
通讯作者:
通讯机构: [3]Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Capital Medical University, Beijing 100069, China [4]Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China [*1]Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)